Executive Management Team
John Didsbury, Ph.D.
President & CEO, Chairman of the Board
Dr. Didsbury is a seasoned Executive Manager with over 26 years of experience within the pharmaceutical and biotechnology industries in both small and large public and private companies. Dr. Didsbury was President/COO/CSO of DARA BioSciences, Inc. (now Midatech Pharma US (NASDAQ:CM – MTP). At DARA he led the development of T3D-959 and directed all operations of the business, overseeing all finances, financing efforts, business development, human resources and administration and directing all drug discovery programs of the company in a CSO role. He played a key role in taking the company public in 2008 through a reverse merger. Prior to DARA, Dr. Didsbury served as CEO of Nuada Pharmaceuticals Inc. Prior to his tenure at Nuada Dr. Didsbury was Head of Strategy and Operations at GlaxoSmithKline, Inc. Previously, Dr. Didsbury served as Associate Director of Biology at Macronex, Inc., as Assistant Professor of Medicine at Duke University Medical Center and as a scientist at Genentech, Inc.
Warren Strittmatter, M.D.
Chief Medical Officer
Dr. Strittmatter was Professor and former Chief of Neurology at Duke University Medical Center. He received his M.D. and Neurology Residency training at Duke University Medical Center, and then subsequently did post-doctoral research at the National Institutes of Health. Dr. Strittmatter is internationally recognized for his basic research in Alzheimer’s and Huntington’s disease. He was elected to the Association of American Physicians, the American Society for Clinical Investigation, and received the Alzheimer’s Association Zenith Award. He was recognized by the Institute for Scientific Information as the “Top 20 Scientists” in Neuroscience and Behavior for the decade 1992-2002. Dr. Strittmatter has published over 100 papers in peer-reviewed academic journals and has been awarded 12 U.S. Patents. He served on the Board of Directors of the Ruth K. Broad Biomedical Research Foundation for over fifteen years, a not-for-profit foundation focused on fostering basic research in Alzheimer’s disease.
Dr Strittmatter received his MD from Duke University.
Stan Chamberlain, Ph.D.
Chief Scientific Officer
Before joining T3D Therapeutics, Dr. Chamberlain served as Chief Scientific Officer for PurThread Technologies, Inc. He was responsible for chemistry and biology for PurThread from June of 2012 until November of 2013. Prior to joining PurThread, Dr. Chamberlain served as Vice President of Chemistry at Inhibitex, Inc. from early 2008 to 2012 where he was responsible for the research and development of the anti-HCV compound INX-08189, working with academic and industrial collaborators. Prior to joining Inhibitex, he was Senior Group Manager in Medicinal Chemistry Oncology at Glaxo SmithKline in Research Triangle Park, NC from 2001 to 2007, working in the area of protein kinase inhibitors. From 1995 to 2001, Dr. Chamberlain was a Group Leader in Medicinal Chemistry at Glaxo Wellcome, working in the areas of antiviral and anti-inflammatory chemotherapy. From 1986 to 1995, he held several Senior Scientist positions in the Experimental Therapy Department at Burroughs Wellcome, focusing on nucleoside agents for anti-viral and oncology applications. Dr. Chamberlain received his PhD in Synthetic Organic Chemistry from the University of Iowa. Dr. Chamberlain’s publications and patents cover the areas of anti-viral, anti-cancer and anti-inflammation chemotherapy, with a focus on protein kinase inhibitors and nucleoside derivatives.
Hoda Gabriel, PMP
Executive Director Clinical Development
Ms. Gabriel is a clinical research and development professional with 27 years of experience directing, designing, planning, and successfully executing early and late phase clinical drug programs within the pharmaceutical industry. Prior to T3D Therapeutics, she held director‐level positions with GlaxoSmithKline and Talecris (now Grifols), where she led several international programs and teams to successful NDA/MAA submissions. Additionally, she founded two independent clinical research companies. Ms. Gabriel has experience in the development of multiple therapeutic areas including CNS, Urology, Metabolic, Cardiovascular, Pain, Dermatology and Peripheral Arterial Disease.